Search
Search
About
Log in
Join
Experiences with
Venetoclax
Posts
Communities
988 public posts
Filter results
Venetoclax (ABT-199) response rate on del 17p CLL patients (ASH 2015)
Venetoclax
is an orally bioavailable, selective BCL-2 inhibitor that induces apoptosis in CLL cells independent of p53. A phase 1 study of
Venetoclax
showed high response rates in patients with relapsed/refractory CLL, including del(17p) CLL (overall response rate, ORR = 77%).
Venetoclax
is an orally bioavailable, selective BCL-2 inhibitor that induces apoptosis in CLL cells independent of p53. A phase 1 study of
Venetoclax
showed high response rates in patients with relapsed/refractory CLL, including del(17p) CLL (overall response rate, ORR = 77%).
AussieNeil
Administrator
in
CLL Support
8 years ago
The Role of BCL2 Inhibition in CLL
Friends, To understand why BCL-2 is such an attractive target in CLL and with the promise of
venetoclax
(ABT-199) hopefully coming soon, here is the very easy to digest nine minute lecture given by Dr.
Friends, To understand why BCL-2 is such an attractive target in CLL and with the promise of
venetoclax
(ABT-199) hopefully coming soon, here is the very easy to digest nine minute lecture given by Dr.
bkoffman
CLL CURE Hero
in
CLL Support
8 years ago
Integrating Emerging Evidence Into the Management of CLL Patients; what leading CLL experts recommend in 4 case studies
(Second Generation BCL-2 inhibitor)
Venetoclax
+ Rituximab and of course..
(Second Generation BCL-2 inhibitor)
Venetoclax
+ Rituximab and of course..
AussieNeil
Administrator
in
CLL Support
8 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
The Future Role of FCR and new data on venetoclax and rituximab
We also share my comments and background on an important oral abstract presented at the 20th Congress of the European Hematology Association (EHA), June 11-15, 2015 on
venetoclax
(ABT-199 or GDC-199) and rituximab.
We also share my comments and background on an important oral abstract presented at the 20th Congress of the European Hematology Association (EHA), June 11-15, 2015 on
venetoclax
(ABT-199 or GDC-199) and rituximab.
bkoffman
CLL CURE Hero
in
CLL Support
9 years ago
For Refractory CLL, Venetoclax's (ABT-199's) Complete Response Rate Is Tops
The complete response rate seen with
venetoclax
is especially notable, said lead investigator Andrew W. Roberts, MBBS, PhD, from the Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, in Australia."
The complete response rate seen with
venetoclax
is especially notable, said lead investigator Andrew W. Roberts, MBBS, PhD, from the Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, in Australia."
AussieNeil
Administrator
in
CLL Support
9 years ago
Venetoclax (ABT-199) Receives Breakthrough Therapy Designation In Relapsed Or Refractory CLL In Previously Treated 17p deletion Patients
This breakthrough designation - only for relapsed/refractory 17p deletion patients should mean the path to FDA approval will be smooth and short in the USA. This is very good news for my fellow American patients with 17p del. Hope the rest of the world stays in step. We are only going to beat this cancer
This breakthrough designation - only for relapsed/refractory 17p deletion patients should mean the path to FDA approval will be smooth and short in the USA. This is very good news for my fellow American patients with 17p del. Hope the rest of the world stays in step. We are only going to beat this cancer
bkoffman
CLL CURE Hero
in
CLL Support
9 years ago
Assessing Response With Novel Agents in CLL - OncLive Peer Exchange
Kipps, MD, UCSD; Shuo Ma, MD, PhD, Northwestern http://www.onclive.com/peer-exchange/non-hodgkins-lymphoma/Assessing-the-Utility-of-MRD-Measures-Versus-CT-Scans The discussion covers: - Inhibition of Rituximab by Ibrutinib - ABT-199 (
Venetoclax
) - ABT-199's remarkable ability to get complete remission
Kipps, MD, UCSD; Shuo Ma, MD, PhD, Northwestern http://www.onclive.com/peer-exchange/non-hodgkins-lymphoma/Assessing-the-Utility-of-MRD-Measures-Versus-CT-Scans The discussion covers: - Inhibition of Rituximab by Ibrutinib - ABT-199 (
Venetoclax
) - ABT-199's remarkable ability to get complete remission
AussieNeil
Administrator
in
CLL Support
9 years ago
Venetoclax(ABT-199)/rituximab achieved an Overall Rate of Response of 88%
(ABT-199)Plus Rituximab Well Tolerated With Promising Activity in Patients With Relapsed/Refractory CLL
Venetoclax
/rituximab achieved ORR of 88% in early investigation and 400 mg identified as the recommended dose for future studies. http://www.clinicaloptions.com/Oncology/Conference
(ABT-199)Plus Rituximab Well Tolerated With Promising Activity in Patients With Relapsed/Refractory CLL
Venetoclax
/rituximab achieved ORR of 88% in early investigation and 400 mg identified as the recommended dose for future studies. http://www.clinicaloptions.com/Oncology/Conference
AussieNeil
Administrator
in
CLL Support
9 years ago
1
...
49
50
10
20
30
40
50
Filter results
Clear filters
Posted in
All communities
CLL Support
943 results
CLL America Support
23 results
Leukaemia CARE
10 results
View top 10 communities
Sort by
Most Relevant
Newest